<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01639521</url>
  </required_header>
  <id_info>
    <org_study_id>4B-10-5</org_study_id>
    <secondary_id>NCI-2012-00961</secondary_id>
    <nct_id>NCT01639521</nct_id>
  </id_info>
  <brief_title>Gemcitabine Hydrochloride and Cisplatin or High-Dose Methotrexate, Vinblastine, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Urothelial Cancer</brief_title>
  <official_title>Randomized Phase II Trial Of Adjuvant Chemotherapy For Urothelial Carcinoma Comparing GC To Dose-Dense MVAC</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Southern California</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Southern California</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is about two chemotherapy study drug combinations (regimens) that are used for&#xD;
      urothelial (bladder or upper urinary tract) cancer. Both study drug regimens, gemcitabine&#xD;
      (gemcitabine hydrochloride) plus cisplatin, and high-dose-intensity MVAC (methotrexate,&#xD;
      vinblastine, doxorubicin plus cisplatin), are standard chemotherapy regimens. Both regimens&#xD;
      are used to treat people with urothelial cancer that has spread to other organs. Both study&#xD;
      drug regimens have been proven to be effective in lowering the risk of the cancer coming&#xD;
      back, but it is not known which regimen is the best. This study hopes to learn whether there&#xD;
      is a difference in the effectiveness and side effects of these two study drug regimens when&#xD;
      they are given to people who have had their urothelial cancer completely removed.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES&#xD;
&#xD;
      To estimate the difference in the rate of unacceptable toxicity for dose-dense methotrexate,&#xD;
      vinblastine, doxorubicin, and cisplatin (MVAC) and gemcitabine and cisplatin (GC) in the&#xD;
      adjuvant treatment of urothelial cancer.&#xD;
&#xD;
      SECONDARY OBJECTIVES&#xD;
&#xD;
      To compare rates of disease recurrence at 3 years between dose-dense MVAC and GC.&#xD;
&#xD;
      To determine whether molecular markers excision repair cross-complementing-1 (ERCC-1)&#xD;
      ribonucleoside-diphosphate reductase M-1 (RRM-1), breast cancer 1 (BRCA1) topoisomerase&#xD;
      2-alpha (Top2A) and protein 53 (p53) can predict those patients more likely to benefit from&#xD;
      chemotherapy.&#xD;
&#xD;
      To investigate the potential utility of cytidine deaminase (CDA), ERCC-1, xeroderma&#xD;
      pigmentosum group D (XPD), glutathione S-transferase P-1 (GSTP-1) and glutathione&#xD;
      S-transferase M-1 (GSTM-1) as molecular markers which predict occurrence of significant&#xD;
      toxicity during adjuvant chemotherapy for urothelial cancer.&#xD;
&#xD;
      OUTLINE: Patients are randomized to 1 of 2 treatment arms.&#xD;
&#xD;
      ARM A: Patients receive cisplatin intravenously (IV) on day 1 and gemcitabine hydrochloride&#xD;
      IV over 1 hour on days 1 and 8. Treatment repeats every 21 days for 4 courses in the absence&#xD;
      of disease progression or unacceptable toxicity.&#xD;
&#xD;
      ARM B: Patients receive methotrexate IV on day 1, vinblastine IV, doxorubicin hydrochloride&#xD;
      IV, cisplatin IV on day 2 and pegfilgrastim subcutaneously (SC) on day 3. Treatment repeats&#xD;
      every 14 days for 4 courses in the absence of disease progression or unacceptable toxicity.&#xD;
      After completion of study treatment, patients are followed up every 3 months for 3 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Lack of funding&#xD;
  </why_stopped>
  <start_date>May 2013</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of unacceptable toxicity graded according to Common Terminology Criteria (CTC) v4.0</measure>
    <time_frame>Assessed up to 3 years</time_frame>
    <description>80% confidence intervals (CI) will be constructed; for unacceptable toxicity, the confidence interval will be one-sided.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival</measure>
    <time_frame>From radical cystectomy to the time cancer recurrence is detected by clinical findings or during surveillance imaging, at 3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Anterior Urethral Cancer</condition>
  <condition>Localized Transitional Cell Cancer of the Renal Pelvis and Ureter</condition>
  <condition>Posterior Urethral Cancer</condition>
  <condition>Recurrent Bladder Cancer</condition>
  <condition>Recurrent Urethral Cancer</condition>
  <condition>Regional Transitional Cell Cancer of the Renal Pelvis and Ureter</condition>
  <condition>Stage III Bladder Cancer</condition>
  <condition>Transitional Cell Carcinoma of the Bladder</condition>
  <condition>Ureter Cancer</condition>
  <condition>Urethral Cancer Associated With Invasive Bladder Cancer</condition>
  <arm_group>
    <arm_group_label>Arm A (gemcitabine hydrochloride, cisplatin)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive cisplatin IV on day 1 and gemcitabine hydrochloride IV over 1 hour on days 1 and 8. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B (MVAC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive methotrexate IV on day 1 and vinblastine IV, doxorubicin hydrochloride IV, and cisplatin IV on day 2. Treatment repeats every 14 days for 4 courses in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm A (gemcitabine hydrochloride, cisplatin)</arm_group_label>
    <arm_group_label>Arm B (MVAC)</arm_group_label>
    <other_name>CACP</other_name>
    <other_name>CDDP</other_name>
    <other_name>CPDD</other_name>
    <other_name>DDP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm A (gemcitabine hydrochloride, cisplatin)</arm_group_label>
    <other_name>dFdC</other_name>
    <other_name>difluorodeoxycytidine hydrochloride</other_name>
    <other_name>gemcitabine</other_name>
    <other_name>Gemzar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methotrexate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm B (MVAC)</arm_group_label>
    <other_name>amethopterin</other_name>
    <other_name>Folex</other_name>
    <other_name>methylaminopterin</other_name>
    <other_name>Mexate</other_name>
    <other_name>MTX</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vinblastine</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm B (MVAC)</arm_group_label>
    <other_name>Velban</other_name>
    <other_name>Velsar</other_name>
    <other_name>VLB</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm B (MVAC)</arm_group_label>
    <other_name>ADM</other_name>
    <other_name>ADR</other_name>
    <other_name>Adria</other_name>
    <other_name>Adriamycin PFS</other_name>
    <other_name>Adriamycin RDF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>pegfilgrastim</intervention_name>
    <description>Given SC</description>
    <arm_group_label>Arm B (MVAC)</arm_group_label>
    <other_name>Filgrastim SD-01</other_name>
    <other_name>GCSF-SD01</other_name>
    <other_name>Neulasta</other_name>
    <other_name>SD-01 sustained duration G-CSF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm A (gemcitabine hydrochloride, cisplatin)</arm_group_label>
    <arm_group_label>Arm B (MVAC)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed high-grade urothelial carcinoma, stage T3bN0, T4N0 or any T&#xD;
             stage with lymph node involvement, completely resected; including upper tract&#xD;
             urothelial carcinoma&#xD;
&#xD;
          -  The dominant histology must be transitional cell or urothelial but foci of other&#xD;
             histologies less than 20 percent of the total tumor volume are permitted&#xD;
&#xD;
          -  Absence of metastatic disease on radiographic imaging&#xD;
&#xD;
          -  Patients must be enrolled and able to start treatment within 90 days of radical&#xD;
             cystectomy or radical nephrectomy&#xD;
&#xD;
          -  Creatinine less than institutional upper limit of normal (ULN) or clearance greater or&#xD;
             equal to 50 mL/min (may be calculated by Cockcroft-Gault formula or measured from&#xD;
             24-hour urine collection)&#xD;
&#xD;
          -  Serum total bilirubin less or equal to 1.5 x ULN (except for patients with Gilbert's)&#xD;
&#xD;
          -  Alkaline phosphatase less or equal to 2.5 x ULN&#xD;
&#xD;
          -  Serum glutamic oxaloacetic transaminase (SGOT) and serum glutamic pyruvate&#xD;
             transaminase (SGPT) less or equal to 2.5 x ULN&#xD;
&#xD;
          -  White blood cells (WBC) greater or equal to 3000&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) greater or equal to 1500&#xD;
&#xD;
          -  Hemoglobin (Hb) greater or equal to 9&#xD;
&#xD;
          -  Platelets greater or equal to 100,000&#xD;
&#xD;
          -  Normal left ventricular ejection fraction, by echocardiogram or multi gated&#xD;
             acquisition scan (MUGA)&#xD;
&#xD;
          -  Patients must be recovered from surgery&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1&#xD;
&#xD;
          -  Willing and able to provide informed consent&#xD;
&#xD;
          -  Willingness to use barrier contraception during study period&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The presence of significant pleural effusion or ascites&#xD;
&#xD;
          -  Prior systemic chemotherapy for urothelial carcinoma including neoadjuvant&#xD;
             chemotherapy (prior intravesical therapy is permitted)&#xD;
&#xD;
          -  History of malignancy within preceding 5 years, aside from non-melanoma skin cancer or&#xD;
             previously treated or incidentally detected prostate cancer with undetectable PSA&#xD;
             (after radical cystectomy or prostate cancer therapy)&#xD;
&#xD;
          -  Peripheral neuropathy greater than grade 1&#xD;
&#xD;
          -  The presence of active heart disease such as congestive heart failure or unstable&#xD;
             angina&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tanya Dorff</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Southern California</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>January 2014</verification_date>
  <study_first_submitted>July 10, 2012</study_first_submitted>
  <study_first_submitted_qc>July 11, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 12, 2012</study_first_posted>
  <last_update_submitted>January 27, 2014</last_update_submitted>
  <last_update_submitted_qc>January 27, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 29, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Transitional Cell</mesh_term>
    <mesh_term>Urethral Neoplasms</mesh_term>
    <mesh_term>Kidney Neoplasms</mesh_term>
    <mesh_term>Ureteral Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Vinblastine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

